This clinical trial is focused on studying a condition known as smoldering multiple myeloma, which is a type of blood cancer that has a high risk of progressing to a more serious form called symptomatic myeloma. The study aims to evaluate the effectiveness of a combination of treatments in patients under 70 years old who are at high risk of this progression. The treatments being studied include carfilzomib, lenalidomide, and dexamethasone, which are used as initial therapy. This is followed by a high-dose treatment with melphalan and a procedure called autologous peripheral blood stem cell transplantation, where a patient’s own blood stem cells are used to help recover from the high-dose treatment.
After the initial treatment and transplantation, patients will receive further treatment with the combination of carfilzomib, lenalidomide, and dexamethasone, known as consolidation therapy, to strengthen the response to the initial treatment. Finally, patients will continue with maintenance therapy using lenalidomide and dexamethasone to help keep the disease under control. The study will also involve the use of pomalidomide in different dosages, which is another medication that can help manage multiple myeloma. Additionally, daratumumab, an injection, is part of the study to explore its potential benefits in this treatment plan.
The purpose of the study is to assess how well these treatments work together in achieving a complete response, which means the disease is not detectable using specific tests. The study will monitor patients over a period of time to see how they respond to the treatments and to ensure their safety throughout the process. The goal is to find the best way to manage smoldering multiple myeloma and prevent it from becoming more serious.
Spain 
